Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention.
暂无分享,去创建一个
[1] J. Ioannidis,et al. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. , 2003, Journal of the American College of Cardiology.
[2] E. Topol,et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. , 2002, Journal of the American College of Cardiology.
[3] E. Topol,et al. Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy , 2002, Circulation.
[4] K. Harre,et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). , 2002, Journal of the American College of Cardiology.
[5] E. Topol,et al. Frequency and long-term impact of myonecrosis after coronary stenting. , 2002, European heart journal.
[6] Eric J Topol,et al. Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. , 2002, American heart journal.
[7] A. Colombo,et al. Nothing is lower than 0, and 3 is closer to 0 than to 5 - medicine is not arithmetic. , 2002, European heart journal.
[8] G. Stone,et al. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. , 2002, The American journal of cardiology.
[9] M. Simoons,et al. Minor Myocardial Damage and Prognosis: Are Spontaneous and Percutaneous Coronary Intervention–Related Events Different? , 2002, Circulation.
[10] G. Stone,et al. Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention: A Device-Specific Analysis of 7147 Patients , 2001, Circulation.
[11] G. Stone,et al. Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention , 2001 .
[12] G. Stone,et al. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. , 2001, The American journal of cardiology.
[13] K. Thygesen,et al. Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .
[14] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[15] Patricia Langenberg,et al. Meta-Analysis, Decision Analysis, and Cost Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, 2nd Edition , 2000 .
[16] G. Stone,et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. , 2000, The American journal of cardiology.
[17] G. Stone,et al. Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. , 2000, Journal of the American College of Cardiology.
[18] E. Topol,et al. Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.
[19] G. Stone,et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. , 1999, Circulation.
[20] R. Califf,et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. , 1999, European heart journal.
[21] R. Califf,et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. , 1999, Circulation.
[22] R. Califf,et al. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. , 1999, Journal of the American College of Cardiology.
[23] R. Califf,et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention , 1999 .
[24] R. Califf,et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. , 1999, Journal of the American College of Cardiology.
[25] G. Dangas,et al. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[26] Samin K. Sharma,et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT) , 1998, Circulation.
[27] R. Califf,et al. Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.
[28] H. Arnesen,et al. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. , 1998, European heart journal.
[29] R. Bonow,et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. , 1997, JAMA.
[30] E. Topol,et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.
[31] E. Topol,et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. , 1996, American heart journal.
[32] R. Califf,et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). , 1995, Journal of the American College of Cardiology.
[33] E. Topol,et al. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. , 1995, Circulation.
[34] D. Baim,et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. , 1994, The American journal of cardiology.
[35] Diana B. Petitti,et al. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .